Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma. A Phase II Multicenter Study "BENTLY".

Trial Profile

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma. A Phase II Multicenter Study "BENTLY".

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Bendamustine (Primary)
  • Indications Cutaneous T cell lymphoma; Peripheral T-cell lymphoma; T cell lymphoma
  • Focus Therapeutic Use
  • Acronyms BENTLY
  • Most Recent Events

    • 08 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 22 Aug 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top